scholarly journals Poor Vitamin Status is Associated with Skeletal Muscle Loss and Mucositis in Head and Neck Cancer Patients

Nutrients ◽  
2018 ◽  
Vol 10 (9) ◽  
pp. 1236 ◽  
Author(s):  
Sara Nejatinamini ◽  
Brock Debenham ◽  
Robin Clugston ◽  
Asifa Mawani ◽  
Matthew Parliament ◽  
...  
Keyword(s):  
Body Composition ◽  
Head And Neck Cancer ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Muscle Loss ◽  
Dietary Intakes ◽  
Food Record ◽  
Computed Tomography Images ◽  
Vitamin Status

Mucositis and muscle wasting are two common toxicity effects of cancer treatment in head and neck cancer (HNC). There is limited data evaluating cancer treatment toxicities in relation to vitamin status. This study aimed to assess changes in vitamin status during HNC treatment in relation to body composition, inflammation and mucositis. In this prospective cohort study, dietary intakes (3-day food record), plasma levels of vitamins and C-reactive protein (CRP) were assessed at baseline (at diagnosis) and post-treatment (after 6–8 weeks of radiation therapy with or without chemotherapy). Computed tomography images were used to quantify body composition. Mucositis information was collected from health records of patients. Twenty-eight HNC patients (age 60 ± 10 years) completed both study time points. Patients who developed mucositis had significantly lower dietary intake of vitamins and plasma 25-hydroxy vitamin D (25-OHD) and all-trans retinol levels (p < 0.02). Patients lost a considerable amount of muscle mass (3.4 kg) and fat mass (3.6 kg) over the course of treatment. There was a trend toward greater muscle loss in patients with 25-OHD < 50 nmol/L compared to patients with 25-OHD ≥ 50 nmol/L (p = 0.07). A significant negative correlation was found between plasma all-trans retinol and CRP level at the end of treatment (p = 0.03). Poor vitamin status could be a contributing factor in developing treatment-induced toxicities.

scholarly journals Meeting Minimum ESPEN Energy Recommendations Is Not Enough to Maintain Muscle Mass in Head and Neck Cancer Patients

Nutrients ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 2743 ◽  
Author(s):  
Benjamin McCurdy ◽  
Sara Nejatinamini ◽  
Brock J. Debenham ◽  
Mirey Álvarez-Camacho ◽  
Catherine Kubrak ◽  
...  
Keyword(s):  
Body Composition ◽  
Head And Neck Cancer ◽  
Dietary Intake ◽  
Head And Neck ◽  
Muscle Mass ◽  
Neck Cancer ◽  
Protein Intake ◽  
Post Treatment ◽  
Muscle Loss ◽  
Dietary Intakes

The relationship between dietary intake and body composition changes during cancer treatment has not been well characterized. The aim of this study was to compare dietary intake at diagnosis and end of treatment in relation to changes in muscle mass and adiposity in head and neck cancer (HNC) patients. Dietary intakes (three-day food record) and body composition using computed tomography (CT) were assessed at diagnosis (baseline) and after treatment completion (post-treatment). Skeletal muscle (SM) loss was explored as a consequence of energy and protein intake in relation to the minimum and maximum European Society of Parenteral and Enteral Nutrition (ESPEN) guidelines. Higher energy intakes (kcal/kg/day) and increases in energy intake (%) from baseline to post-treatment were correlated with attenuated muscle loss (r = 0.62, p < 0.01; r = 0.47, p = 0.04, respectively). Post-treatment protein intake demonstrated a weak positive correlation (r = 0.44, p = 0.05) with muscle loss, which did not persist when controlling for covariates. Meeting minimum ESPEN energy guidelines (25 kcal/kg/day) did not attenuate SM loss, whereas intakes >30 kcal/kg/day resulted in fewer participants losing muscle. Greater baseline adiposity correlated with greater SM loss (p < 0.001). Energy intakes of 30 kcal/kg/day may be required to protect against SM loss during treatment in HNC patients. The influence of adiposity on SM loss requires further exploration.

P2.49. Changes in body composition during and after head and neck cancer treatment: Preliminary results

2009 ◽  
Vol 3 (1) ◽  
pp. 177
Author(s):  
H. Jager-Wittenaar ◽  
P.U. Dijkstra ◽  
J.A. Langendijk ◽  
B.F.A.M. van der Laan ◽  
J. Pruim ◽  
...  
Keyword(s):  
Body Composition ◽  
Head And Neck Cancer ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Preliminary Results

scholarly journals Incidence of Oral Mucositis in Patients Undergoing Head and Neck Cancer Treatment: Systematic Review and Meta-Analysis

2021 ◽  
Vol 5 (1) ◽  
pp. 23
Author(s):  
Raquel Pacheco ◽  
Maria Alzira Cavacas ◽  
Paulo Mascarenhas ◽  
Pedro Oliveira ◽  
Carlos Zagalo
Keyword(s):  
Systematic Review ◽  
Head And Neck Cancer ◽  
Oral Health ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Oral Mucositis ◽  
Negative Impact ◽  
Meta Analysis ◽  
Incidence Rates

This systematic review and meta-analysis aimed to assess the literature about the incidence of oral mucositis and its degrees (mild, moderate, and severe), in patients undergoing head and neck cancer treatment (radiotherapy, chemotherapy, and surgery). Addressing this issue is important since oral mucositis has a negative impact on oral health and significantly deteriorates the quality of life. Therefore, a multidisciplinary team, including dentists, should be involved in the treatment. The overall oral mucositis incidence was 89.4%. The global incidence for mild, moderate, and severe degrees were 16.8%, 34.5%, and 26.4%, respectively. The high incidence rates reported in this review point out the need for greater care in terms of the oral health of these patients.

scholarly journals FYNN—Support Program for Patients Who Have Completed Head and Neck Cancer Treatment

2018 ◽  
Vol 100 (5) ◽  
pp. 1401
Author(s):  
L. Mullis ◽  
G. Dawson ◽  
L. Herring ◽  
B. Neff ◽  
D. Salisbury ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Support Program

Effect of Epoetin Alfa on Survival and Cancer Treatment–Related Anemia and Fatigue in Patients Receiving Radical Radiotherapy With Curative Intent for Head and Neck Cancer

2009 ◽  
Vol 27 (34) ◽  
pp. 5751-5756 ◽  
Author(s):  
Peter J. Hoskin ◽  
Martin Robinson ◽  
Nicholas Slevin ◽  
David Morgan ◽  
Kevin Harrington ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Adverse Events ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Functional Assessment ◽  
Radical Radiotherapy ◽  
Epoetin Alfa ◽  
Local Tumor ◽  
Curative Intent

Purpose To evaluate the effect of epoetin alfa on local disease-free survival (DFS), overall survival (OS), and cancer treatment–related anemia and fatigue in patients with head and neck cancer receiving radical radiotherapy with curative intent. Patients and Methods Patients (N = 301) with hemoglobin (Hb) less than 15 g/dL were randomly assigned in a ratio of 1:1 to receive radiotherapy plus epoetin alfa (10,000 U subcutaneously [SC] three times weekly if baseline Hb was < 12.5 g/dL; 4,000 U SC three times weekly if baseline Hb ≥ 12.5 g/dL) or radiotherapy alone. Hb levels were monitored weekly. The primary end point was local DFS, defined as the time from random assignment to local disease recurrence or death. Secondary efficacy end points included OS, local tumor response, and local tumor control. Patients were followed at 1, 4, 8, and 12 weeks postradiotherapy and annually for 5 years. Cancer treatment–related anemia and fatigue were evaluated with the Functional Assessment of Cancer Therapy-Anemia and Functional Assessment of Cancer Therapy-Head and Neck. Adverse events were recorded up to 12 weeks postradiotherapy. Results Hb levels increased from baseline with epoetin alfa. The median duration of local DFS was not statistically different between groups (observation, 35.42 months; epoetin alfa, 31.47 months; hazard ratio, 1.04; 95% CI, 0.77 to 1.41). Groups did not significantly differ in DFS, OS, tumor outcomes, or cancer treatment–related anemia or fatigue. No new or unexpected adverse events were observed. Conclusion Addition of epoetin alfa to radical radiotherapy did not affect survival, tumor outcomes, anemia, or fatigue positively or negatively in patients with head and neck cancer.

Molecular Oncology for the Head and Neck Surgeon

1995 ◽  
Vol 112 (5) ◽  
pp. P88-P89
Author(s):  
Norris K. Lee
Keyword(s):  
Head And Neck Cancer ◽  
Molecular Biology ◽  
Cancer Treatment ◽  
Head And Neck ◽  
Neck Cancer ◽  
Cancer Model ◽  
Educational Objectives ◽  
Molecular Oncology ◽  
The Future ◽  
Biological Concepts

Educational objectives: To understand basic molecular biological concepts and breakthroughs as they apply to the head and neck cancer model and to envision the future of head and neck cancer treatment, within the context of molecular biology.

Sign in / Sign up

Export Citation Format

Share Document